SB 204741, , >98% (HPLC)

SB 204741, , >98% (HPLC)

Application

SB 204741 has been used as a 5-hydroxytryptamine receptor 2B (Htr2B) antagonist: to inhibit Htr2b signaling to test its effect on hepatic stellate cell (HSC) activation in three-month-old adult zebrafishto test its effect on the inhibition of fluoxetine effects in depressive-like behavioral studies in miceto test its effect in reducing scratching behavior evoked by sertraline in mice

Biochem/physiol Actions

5-HT2B serotonin receptor antagonist.

SB 204741 reduces the synaptic facilitation induced by the low dose of buprenorphine in spinal C-fiber synapses.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold for research purposes under agreement from GlaxoSmithKline

Packaging

10, 50 mg in glass bottle

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Quality Level InChI key InChI Manufacturer Form Assay Price Quantity
3573888 SB 204741, , >98% (HPLC) off-white to tan 100 USFUFHFQWXDVMH-UHFFFAOYSA-N 1S/C14H14N4OS/c1-9-7-13(20-17-9)16-14(19)15-11-3-4-12-10(8-11)5-6-18(12)2/h3-8H,1-2H3,(H2,15,16,19)
£256.29 (exc VAT) per 10MG
-
+
3573889 SB 204741, , >98% (HPLC) off-white to tan 100 USFUFHFQWXDVMH-UHFFFAOYSA-N 1S/C14H14N4OS/c1-9-7-13(20-17-9)16-14(19)15-11-3-4-12-10(8-11)5-6-18(12)2/h3-8H,1-2H3,(H2,15,16,19)
£947.14 (exc VAT) per 50MG
-
+